Date: 2016-09-13
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the Progress in Vaccination Against Cancer (PIVAC) Conference in Winchester
Company: Galena Biopharma (USA - OR)
Product: NeuVax™ (nelipepimut-S)
Action
mechanism:
- peptide/immunotherapy product. NeuVax™ (nelipepimut-S) is an immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, which is expressed in ovarian and pancreatic cancers as well as in breast cancer. NeuVax™ has been shown to bind to HLA-A2 and A3, as well as HLA-A24 and A26 molecules. The nelipepimut-S sequence stimulates specific CD8+ cytotoxic T lymphocytes (CTLs) following binding to specific HLA molecules on antigen presenting cells (APC). These activated specific CTLs recognize, neutralize and destroy, through cell lysis, HER2 expressing cancer cells, including occult cancer cells and micrometastatic foci. The nelipepimut-S immune response can also generate CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading leading to a broader, more robust anti-tumor immune response.
Disease: ovarian cancer, pancreatic cancer
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On September 13, 2016, Galena Biopharma announced that preclinical data from NeuVax™ (nelipepimut-S) program is being presented at the Progress in Vaccination Against Cancer (PIVAC) Conference in Winchester, UK. The poster, entitled, “Preclinical study on the efficacy of NeuVax™ peptide vaccine against human Her2+/ HLA-A2.1+ ovarian and pancreatic cancer,” demonstrated the results of HLA-A2 transgenic mice that were immunized with NeuVax (E75) mixed with recombinant mouse GM-CSF (NeuVax mice). As control, a group of mice received GM-CSF alone (control mice). CD8+ T cells purified from the spleens of HLA-A2 transgenic immunized mice were adoptively transferred to NSG (NOD/SCID/IL2R?null) mice bearing human ovarian or pancreatic tumors which were HER2+, HLA-A2+.
Administration of the NeuVax vaccination resulted in a specific, delayed-type hypersensitivity (DTH) reaction and in the induction of E75 specific CD8+ T cells that express PD-1 (programmed T-cell death protein). Both ovarian and pancreatic tumor growth rate was significantly reduced in NSG mice that received the CD8+ T cells from NeuVax-immunized mice compared to those receiving CD8+ T cells from control mice. Additionally, PD-1 was identified on activated CD8+ T cells.
Is
general: Yes
